12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Dysport abobotulinumtoxinA regulatory update

The Scottish Medicines Consortium recommended the restricted use of Ipsen's Dysport abobotulinumtoxinA on the National Health Service (NHS) in Scotland for focal spasticity of the upper limbs associated with stroke. In 2007, the consortium recommended against the product for the treatment of focal spasticity, including arm symptoms associated with focal...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >